Christine A. Poon - 15 Aug 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Christine A. Poon
Issuer symbol
REGN
Transactions as of
15 Aug 2024
Net transactions value
-$8,072,614
Form type
4
Filing time
19 Aug 2024, 16:01:37 UTC
Previous filing
09 Jul 2024
Next filing
16 Sep 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $4,479,671 +10,838 +499% $413.33* 13,010 15 Aug 2024 Direct
transaction REGN Common Stock Sale $1,169,589 -1,012 -7.8% $1155.72 11,998 15 Aug 2024 Direct F1
transaction REGN Common Stock Sale $2,738,118 -2,368 -20% $1156.30 9,630 15 Aug 2024 Direct F2
transaction REGN Common Stock Sale $1,805,435 -1,560 -16% $1157.33 8,070 15 Aug 2024 Direct F3
transaction REGN Common Stock Sale $245,500 -212 -2.6% $1158.02 7,858 15 Aug 2024 Direct F4
transaction REGN Common Stock Sale $6,205,965 -5,352 -68% $1159.56 2,506 15 Aug 2024 Direct F5
transaction REGN Common Stock Sale $271,545 -234 -9.3% $1160.45 2,272 15 Aug 2024 Direct F6
transaction REGN Common Stock Sale $116,132 -100 -4.4% $1161.32 2,172 15 Aug 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -10,838 -100% $0.000000* 0 15 Aug 2024 Common Stock 10,838 $413.33 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents volume-weighted average price of sales of 1,012 shares of Company stock on August 15, 2024 at prices ranging from $1,155.38 to $1,155.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
F2 Represents volume-weighted average price of sales of 2,368 shares of Company stock on August 15, 2024 at prices ranging from $1,156.04 to $1,156.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
F3 Represents volume-weighted average price of sales of 1,560 shares of Company stock on August 15, 2024 at prices ranging from $1,157.02 to $1,157.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
F4 Represents volume-weighted average price of sales of 212 shares of Company stock on August 15, 2024 at prices ranging from $1,158.01 to $1,158.08. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
F5 Represents volume-weighted average price of sales of 5,352 shares of Company stock on August 15, 2024 at prices ranging from $1,159.18 to $1,159.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
F6 Represents volume-weighted average price of sales of 234 shares of Company stock on August 15, 2024 at prices ranging from $1,160.10 to $1,160.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
F7 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.